ExThera Medical’s CEO Bob Ward Receives Prestigious BioMedSA Award for Innovation in Healthcare and Bioscience Including a Groundbreaking Device to Treat COVID-19
Sep 13, 2022

MARTINEZ, Calif. – On September 8th, BioMedSA honored Robert Ward, President and CEO of ExThera Medical, with the 2021-2022 BioMedSA Award for Innovation in Healthcare and Bioscience, for his numerous achievements in the medical device industry, including the development of the Seraph® 100 Microbind® Affinity Blood Filter, a groundbreaking device that has been used in the treatment of critically ill COVID-19 patients. The ceremony was held in the new Tech Center in Port San Antonio TX. It was attended by more than 400 people, including clinicians and administrators and the mayor of San Antonio TX, a major hub of MedTech and military and civilian medicine.

The BioMedSA Award for Innovation in Healthcare and Bioscience celebrates local and national innovators in the healthcare and bioscience field, including patient care, education, research and development, leadership, public policy and medical technology. The list of past winners is a who’s who of the field.

“We are happy that the Seraph 100 is making a positive impact during the COVID-19 pandemic under our FDA Emergency Use Authorization,” said ExThera Medical CEO Robert Ward. “It is an incredible honor to be recognized by one’s peers and by a highly regarded organization such as BioMedSA.”

Prior to ExThera Medical, Robert Ward led several companies whose innovations have benefitted patients, including as President/CEO and founder of the Polymer Technology Group (PTG), President of the Biomaterials Division at Thoratec and Director of Research at Avco Medical Products. He has numerous technical publications and patents and has received multiple awards and recognitions.

“We are proud to honor Robert Ward for his lifetime of achievements in the MedTech industry,” noted BioMedSA President Heather Hanson. “His entire career of innovation, invention and commercialization of technologies has made an indelible impact on patients around the world, most recently during the COVID-19 pandemic.”

The Seraph 100 has been granted Emergency Use Authorization by the Food and Drug Administration to treat COVID-19 patients admitted to the ICU with confirmed or imminent respiratory failure, and has been used on more than 1,000 US and EU patients since April 2020. A multicenter randomized controlled trial studying blood purification for the treatment of pathogen-associated shock during sepsis (PURIFY-RCT) began enrollment earlier this year. Seraph attained a CE Mark in the EU countries where it has been used successfully to treat COVID-19 and a variety of other bloodstream infections.


About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, or field hospitals to address nosocomial and community-acquired infections as well as those caused by battlefield wounds and pandemics. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis and other severe infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US, the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph 100® has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.
For more information visit the company’s website at www.extheramedical.com.

About Seraph 100
As a patient’s blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.
For more news stories on the Seraph 100 click here.

All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.

MM0006 Rev B